Ensysce Biosciences Inc (ENSC)vsBeiGene, Ltd. (ONC)
ENSC
Ensysce Biosciences Inc
$0.40
-3.16%
HEALTHCARE · Cap: $7.55M
ONC
BeiGene, Ltd.
$372.49
-0.88%
HEALTHCARE · Cap: $42.08B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 136075% more annual revenue ($6.13B vs $4.50M). ONC leads profitability with a 10.7% profit margin vs -280.5%. ONC earns a higher WallStSmart Score of 62/100 (C+).
ENSC
Avoid28
out of 100
Grade: F
ONC
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.7%
Fair Value
$0.74
Current Price
$0.40
$0.34 discount
Margin of Safety
+80.2%
Fair Value
$1776.44
Current Price
$372.49
$1403.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1149.0% — below average capital efficiency
Trading at 8.1x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ENSC
The strongest argument for ENSC centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : ENSC
The primary concerns for ENSC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 66.7x leaves little room for execution misses.
Key Dynamics to Monitor
ENSC profiles as a turnaround stock while ONC is a growth play — different risk/reward profiles.
ENSC carries more volatility with a beta of 0.90 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (62/100 vs 28/100) and 29.6% revenue growth. ENSC offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ensysce Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?